Doxazosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C23H25N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NW1291F1W8, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin but generally known as doxazosin, which bears US NIH Compound Identifier 3157. European Medicines Agency schedules Doxazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06384MIG. The term DOXAZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules doxazosin in its Anatomical Therapeutic Chemical (ATC) Classification. DOXAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxazosin under HS 29349990 and SITC 51579. As of Q4 2014, DOXAZOSIN remains the US FDA Preferred Term for this commodity. Doxazosin bears US NLM identifiers UMLS ID C0114873 and NCI Concept Code C61737. SMILES: O1C(C(=O)N2CCN(CC2)C2NC3C(C(N2)N)CC(OC)C(OC)C3)COC2C1CCCC2.